LIGAND PHARMACEUTICALS (LGND) Stock Price, Forecast & Analysis
NASDAQ:LGND • US53220K5048
LGND Key Statistics, Chart & Performance
The current stock price of LGND is 199.7 USD. In the past month the price increased by 1.61%. In the past year, price increased by 62.24%.
LGND Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to LGND. When comparing the yearly performance of all stocks, LGND is one of the better performing stocks in the market, outperforming 84.97% of all stocks.
LGND Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to LGND. LGND scores excellent on profitability, but there are some minor concerns on its financial health.
LGND Financial Highlights
Over the last trailing twelve months LGND reported a non-GAAP Earnings per Share(EPS) of 8.04. The EPS increased by 40.81% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 19.34% | ||
| ROA | 3.29% | ||
| ROE | 5.11% | ||
| Debt/Equity | 0.47 |
LGND Forecast & Estimates
14 analysts have analysed LGND and the average price target is 248.31 USD. This implies a price increase of 24.34% is expected in the next year compared to the current price of 199.7.
For the next year, analysts expect an EPS growth of 5.22% and a revenue growth 9.77% for LGND
LGND Ownership
LGND Latest News, Press Relases and Analysis
LGND Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.71 | 994.53B | ||
| JNJ | JOHNSON & JOHNSON | 21.23 | 598.542B | ||
| MRK | MERCK & CO. INC. | 22.47 | 307.324B | ||
| PFE | PFIZER INC | 9.08 | 157.21B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 10.22 | 126.97B | ||
| ZTS | ZOETIS INC | 18.7 | 57.775B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.05 | 26.674B | ||
| VTRS | VIATRIS INC | 5.98 | 17.196B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.7 | 13.117B | ||
| AXSM | AXSOME THERAPEUTICS INC | 200.35 | 8.262B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About LGND
Company Profile
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company that involves clinical development and commercialization of high-value medicines. The company is headquartered in Jupiter, Florida and currently employs 68 full-time employees. The company does this by financing, licensing its technologies or both. The company operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP and BEPro Technology Platform, and Pelican Expression Technology. The company has multiple alliances, licenses and other business relationships with various pharmaceutical companies.
Company Info
LIGAND PHARMACEUTICALS
555 Heritage Drive, Suite 200
Jupiter FLORIDA 92121 US
CEO: John L. Higgins
Employees: 68
Phone: 18585507500
LIGAND PHARMACEUTICALS / LGND FAQ
What does LIGAND PHARMACEUTICALS do?
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company that involves clinical development and commercialization of high-value medicines. The company is headquartered in Jupiter, Florida and currently employs 68 full-time employees. The company does this by financing, licensing its technologies or both. The company operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP and BEPro Technology Platform, and Pelican Expression Technology. The company has multiple alliances, licenses and other business relationships with various pharmaceutical companies.
What is the stock price of LIGAND PHARMACEUTICALS today?
The current stock price of LGND is 199.7 USD. The price increased by 0.7% in the last trading session.
Does LIGAND PHARMACEUTICALS pay dividends?
LGND does not pay a dividend.
How is the ChartMill rating for LIGAND PHARMACEUTICALS?
LGND has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Is LIGAND PHARMACEUTICALS (LGND) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on LGND.
What is the market capitalization of LGND stock?
LIGAND PHARMACEUTICALS (LGND) has a market capitalization of 3.93B USD. This makes LGND a Mid Cap stock.
What is the Short Interest ratio of LIGAND PHARMACEUTICALS (LGND) stock?
The outstanding short interest for LIGAND PHARMACEUTICALS (LGND) is 6.67% of its float.